Posted by Michael Wonder on 03 Feb 2024
Pfizer's Bosulif for leukaemia gains insurance coverage, patients urge inclusion for children, first-line use
3 January 2024 - Pfizer's second generation targeted therapy for chronic myeloid leukaemia, Bosulif (bosutinib), has been newly registered with the health insurance program this month.
A patient group welcomed the news and called for expanding its reimbursement to treat children.
